Design Therapeutics Inc Sustainability Reports
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of small-molecule gene targeted chimera (GeneTAC) molecules. The company focuses on designing therapies to address the underlying causes of inherited nucleotide repeat expansion mutations, such as Friedreich's ataxia and myotonic dystrophy type-1.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00SNC49W7
3 reports from 2021 to 2024
